Medicenna Therapeutics (TSE:MDNA) Sets New 12-Month Low – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price hit a new 52-week low during trading on Tuesday . The company traded as low as C$0.42 and last traded at C$0.43, with a volume of 46475 shares changing hands. The stock had previously closed at C$0.43.

Medicenna Therapeutics Price Performance

The business has a 50-day moving average price of C$0.57 and a 200 day moving average price of C$0.86. The company has a market cap of C$37.96 million, a price-to-earnings ratio of -3.03 and a beta of 2.90. The company has a current ratio of 2.68, a quick ratio of 4.65 and a debt-to-equity ratio of 3.30.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings data on Thursday, April 30th. The company reported C($0.06) EPS for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. As a group, research analysts expect that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.